Trials / Active Not Recruiting
Active Not RecruitingNCT02628067
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,609 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
Conditions
- Advanced Cancer
- Anal Carcinoma
- Anal Cancer
- Biliary Cancer
- Cholangiocarcinoma
- Bile Duct Cancer
- Neuroendocrine Tumor
- Carcinoid Tumor
- Endometrial Carcinoma
- Endometrial Cancer
- Cervical Carcinoma
- Cervical Cancer
- Vulvar Carcinoma
- Vulvar Cancer
- Small Cell Lung Carcinoma
- Small Cell Lung Cancer (SCLC)
- Mesothelioma
- Thyroid Carcinoma
- Thyroid Cancer
- Salivary Gland Carcinoma
- Salivary Gland Cancer
- Salivary Cancer
- Parotid Gland Cancer
- Advanced Solid Tumors
- Colorectal Carcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | pembrolizumab | intravenous infusion |
| BIOLOGICAL | pembrolizumab | intravenous infusion |
Timeline
- Start date
- 2015-12-18
- Primary completion
- 2027-05-04
- Completion
- 2027-05-04
- First posted
- 2015-12-11
- Last updated
- 2025-09-22
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02628067. Inclusion in this directory is not an endorsement.